source
- Crystalys gets $130M to take Sobi-rivaling gout drug to marketA San Diego biotech has raised an additional $130 million to get a gout drug that's already approved in Japan and China onto the US and European markets. Crystalys Therapeutics reeled in the Series…Endpoints · 6d ago↗ source
- Crystalys nets $130M more to push gout drug through late-stage testsThe startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in t…BioPharma Dive · 6d ago↗ source
- Summit reports two-year survival data for Western patients, though context lackingSummit Therapeutics unveiled additional follow-up data on its experimental cancer drug ivonescimab, and how its benefit compares between Asian and Western patients. But key context remains unknown.…